Summary
• AEON Biopharma’s stock rises 13.4% to $0.98 following a strategic equity exchange agreement with Daewoong Pharmaceutical.
• The agreement involves exchanging $15 million in convertible notes for equity and additional financing to support AEON’s BOTOX biosimilar development.
• Trading volume exceeds average levels, indicating increased investor interest amid a volatile trading history.
AEON Biopharma, Inc. (NYSE American: AEON) is witnessing a significant rise, currently priced at $0.98, marking a jump of 13.4% intraday. The company has seen its stock rally following the announcement of a strategic exchange agreement with Daewoong Pharmaceutical, despite the last close price not being available due to its recent market activity.
Exchange Agreement Boosts Investor Sentiment
AEON and Daewoong have executed a definitive agreement to exchange $15 million of convertible notes plus accrued interest for new equity, alongside $1.5 million in new notes due in 2030 and cash-exercise warrants for 8 million shares of common stock. This exchange, which is pending shareholder approval, enhances AEON’s financial position as it seeks to advance the development of its potential BOTOX biosimilar, ABP-450. Announced on December 15, 2025, this move aligns with the company’s goal for accelerated market entry in the U.S.
Investors are responding positively to this announcement, contributing to today’s substantial price increase as market activity ramps up, driven likely by growing confidence in AEON’s strategic direction.
Market Performance Overview
Currently, AEON’s stock displays a relative strength index (RSI) of 52.98, suggesting it is moving within a neutral range. The 20-day simple moving average (SMA) indicates a positive momentum with a 6.2% increase, while the 50-day and 200-day SMAs reflect declines of 5.9% and 17.3%, respectively. This, coupled with 52-week lows recorded at -98.4%, demonstrates a volatile trading history over the past year.
In terms of trading volume, AEON is experiencing robust activity today with nearly 169,179 shares changing hands, eclipsing the average 10-day volume of 159,413 shares. This heightened trading may signal increased interest following the announcement.
Conclusion
As AEON Biopharma progresses through this exchange agreement with Daewoong, it presents a critical juncture for the company. The successful completion of this transaction could provide a solid foundation for AEON’s future growth aspirations in the biopharmaceutical market. Investors remain keenly vigilant on further announcements and shareholder responses related to this deal.